Your session is about to expire
← Back to Search
IRD Regimen for Multiple Myeloma
Study Summary
This trial is testing if a bortezomib-based induction regimen can improve progression-free survival in myeloma patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 45 Patients • NCT03416374Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any uncontrolled heart problems.I can take care of myself and am up and about more than half of my waking hours.I am a woman who cannot become pregnant or will use two birth control methods during the study.I have been diagnosed with multiple myeloma based on all required criteria.I haven't taken specific strong medications or herbal supplements like St. John's wort in the last 14 days.I haven't had any cancer besides nonmelanoma skin cancer or in situ carcinoma, or if I have, it was treated over 2 years ago with no remaining signs.I finished 3 cycles of a specific treatment without my cancer getting worse.I have multiple myeloma and have been treated once before.My stem cell treatment plan has been approved by the Takeda Medical Monitor.My cancer has worsened despite initial treatment.I do not have an active infection or known HIV, hepatitis B, or C.My doctor thinks I can receive the IRD treatment.I have not had a serious infection or needed antibiotics in the last 14 days.I haven't had radiotherapy in the last 14 days, or 7 days if it was a small area.I have moderate to severe nerve damage or mild with pain.My multiple myeloma has spread to my brain or spinal cord.I am a male and agree to use contraception or practice abstinence during and 90 days after the study.I have not had major surgery in the last 14 days.I have been treated with or been part of a study involving ixazomib.I still have mild side effects from my last chemotherapy.
- Group 1: Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings for individuals to participate in this trial?
"Data from clinicaltrials.gov indicates that this medical trial is currently not accepting any additional participants; its initial posting was on September 20th 2017 and it last updated October 28th 2022. Fortunately, there are still 1,523 other trials actively recruiting at the moment."
What are the main applications of Ixazomib?
"Ixazomib is effective at managing ophthalmia, sympathetic conditions and branch retinal vein occlusion. Additionally, it can be administered as a part of multiple systemic chemotherapy regimens."
How many participants are contributing to the results of this clinical research?
"At this time, the trial is not enrolling patients. Although initially posted in September 2017, it was last updated on October 28th 2022. For those looking for similar studies there are 807 trials actively recruiting people with multiple myeloma and 716 clinical investigations searching for volunteers to test Ixazomib treatment."
How many operational sites are overseeing this trial?
"This on-going medical research is hosted by Texas Oncology - Presbyterian Cancer Center Dallas in Dallas, TX, Texas Oncology - San Antonio Northwest in San Antonio, CA and Cancer Center Associates situated at Mesquite Nevada among 24 other sites."
Has the FDA approved Ixazomib for clinical use?
"The safety of Ixazomib was rated at 3, which is the highest score possible due to its approval and Phase 4 status."
Has Ixazomib been evaluated in any other research experiments?
"Ixazomib was first studied nearly two decades ago in 2002 at Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. Since that initial trial, 1375 additional studies have been completed and 716 further clinical trials are presently enrolling participants, with a majority of these being located in the Dallas region of Texas."
Share this study with friends
Copy Link
Messenger